ML345是一种强效和选择性的NLRP3炎症酶抑制剂,具有抗炎活性
Hualong Lin1, Xinxin Liang1, Weijie Hao1
1Department of Gynecology and Obstetrics, Tangdu Hospital, Fourth Military Medical University, Xi'an, Shaanxi Province, China.
Molecular biomedicine
|November 13, 2025
概括
ML345是NLRP3炎症酶的强效和选择性抑制剂,这是炎症性疾病的关键驱动因素. 这种化合物在临床前模型中有效降低炎症,为各种NLRP3相关疾病提供了有前途的治疗候选者.
科学领域:
- 免疫学 免疫学 免疫学
- 药理学 药理学是指药理学的学科.
- 分子生物学分子生物学
背景情况:
- 类似NOD的受体pyrin域含有蛋白3 (NLRP3) 炎症体与许多炎症性疾病有关.
- 目前的NLRP3抑制剂缺乏临床批准,这凸显了对新型治疗剂的需求.
研究的目的:
- 研究ML345作为NLRP3驱动炎症的潜在治疗剂.
- 阐明ML345在抑制NLRP3炎症酶激活中的作用机制.
主要方法:
- 评估ML345对正规,非正规和替代NLRP3炎症酶激活途径的抑制作用.
- 通过生物化学测试确定ML345的结合部位和与NLRP3的相互作用.
- 在系统性炎症和LPS诱导流产的小鼠模型中评估ML345的疗效和安全性.
主要成果:
- ML345有力地和选择性地抑制了NLRP3炎症酶激活,而不影响其他炎症酶.
- ML345在氨酸381处直接与NLRP3结合,破坏NLRP3-NEK7的相互作用,并防止炎症细胞组合.
- ML345在体内表现出显著的治疗效果,在小鼠模型中减轻炎症反应,并显示出良好的耐受性.
结论:
- ML345是一种高度选择性和强大的NLRP3抑制剂,具有独特的作用机制.
- ML345在治疗NLRP3介导的炎症性疾病方面具有显著的治疗潜力.
相关概念视频
01:29Drugs for Treatment of Ulcerative Colitis in IBD
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide generation.
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...